News: OPT Opthea Ltd Says Offer Price For $90 Million Placement Is A$1.15 Per New Share, page-6

Interesting article. I note Opthea has the option to prepay its obligations at any time.

Megan Baldwin is quoted several times.

”This strategic transaction is expected to fund us through Phase 3 top-line data expected in mid-2024 and strengthens our strategic position to maximise the value of OPT-302”

”One of the really good points about the financing is that you can be in a stronger position to move it forward independently. It means we can make the right choices and only do a partnership deal that is
good - we’re not forced into a position of needing to do any one kind of deal, we’re independently funding through to top-line data readout.”

”That said, we’re remain open to partnership, because we recognise you can leverage the expertise and resources of a large pharmaceutical partner.”